Abbott Laboratories $ABT Shares Sold by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,076 shares of the healthcare product maker’s stock after selling 206 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Abbott Laboratories were worth $1,778,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ABT. Hill Island Financial LLC grew its holdings in shares of Abbott Laboratories by 38.2% during the second quarter. Hill Island Financial LLC now owns 3,124 shares of the healthcare product maker’s stock worth $425,000 after purchasing an additional 863 shares during the last quarter. Ergawealth Advisors Inc. boosted its position in shares of Abbott Laboratories by 2.5% in the 2nd quarter. Ergawealth Advisors Inc. now owns 4,283 shares of the healthcare product maker’s stock valued at $583,000 after purchasing an additional 105 shares during the period. Boston Common Asset Management LLC purchased a new position in Abbott Laboratories during the 2nd quarter worth approximately $3,316,000. Clarius Group LLC increased its position in Abbott Laboratories by 4.9% during the second quarter. Clarius Group LLC now owns 11,920 shares of the healthcare product maker’s stock worth $1,621,000 after buying an additional 552 shares during the period. Finally, Quent Capital LLC boosted its holdings in shares of Abbott Laboratories by 13.1% in the second quarter. Quent Capital LLC now owns 6,375 shares of the healthcare product maker’s stock valued at $867,000 after acquiring an additional 736 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. The Goldman Sachs Group upped their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Raymond James Financial lowered their price target on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Abbott Laboratories in a research report on Saturday, September 27th. Finally, BTIG Research dropped their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $145.39.

Abbott Laboratories Stock Down 0.7%

ABT opened at $133.63 on Tuesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The stock has a market capitalization of $232.58 billion, a P/E ratio of 16.75, a P/E/G ratio of 2.55 and a beta of 0.69. The business has a 50 day simple moving average of $132.08 and a 200-day simple moving average of $131.44.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s payout ratio is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.